¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽÉÀåÇÐȸ 2019 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2019-04-19

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѽÉÀåÇÐȸ 2019 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2019-04-19
±³À°ÀÏÀÚ : 2019-04-19
±³À°Àå¼Ò : º¤½ºÄÚ 201È£ ¿Ü  
±³À°ÁÖÁ¦ : 2019 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258  
À̸ÞÀÏ : herz8@circulation.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡   (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ 100,000¿ø/ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ 70,000¿ø´çÀϵî·Ï: ±³¼ö ¹× °³¿øÀÇ 120,000¿ø/ÀüÀÓÀÇ, Àü°øÀÇ, ±âŸ 90,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-19 201È£ 09:30~09:45 º¸Çè ±Þ¿© ÀÌÈÄ LVAD ÇöȲ  °­Çý¿µ(°Ç°­º¸Çè½É»çÆò°¡¿ø) 
±³À°½Ã°£ 04-19 201È£ 09:45~10:00 Indication of LVAD as BTT, BTC or DT: Cardiologist¡¯s View:  ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-19 201È£ 10:00~10:15 Perioperative Management of Patients with LVAD: Surgeon¡¯s View:  Á¶¾çÇö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-19 201È£ 10:15~10:30 Future Perspectives of LVAD in Korea  ÃÖÁø¿À(¼º±Õ°üÀÇ´ë) 
Åä·Ð 04-19 201È£ 10:30~11:00 Discussion  () 
È޽Ġ04-19  11:00~11:10 Break  () 
±³À°½Ã°£ 04-19 103È£ 11:10~11:30 How to Approach to Resistant Hypertension  ÀÓ»óÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-19 103È£ 11:30~11:50 How to Manage Resistant Hypertension  ½ÅÁøÈ£(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-19 103È£ 11:50~12:20 Renal Nerve Denervation: Current and Future  ±èº´±Ø(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-19 103È£ 12:20~12:40 Discussion  () 
È޽Ġ04-19  12:40~12:45 Break  () 
±³À°½Ã°£ 04-19 104È£ 12:45~13:05 Antithrombotic Therapy in Patients with NVAF Undergoing PCI : Should We Change Our Practice?  °­ÇöÀç(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-19 104È£ 13:05~13:25 AUGUSTUS Trial : An Open-label, 2 x 2 Factorial, Randomized Trial to Evaluate the Safety of Apixaban vs.VKA and Aspirin vs. Placebo in Patients with AF and ACS and/or PCI  Renato Delascio Lopes(Duke Univ. USA) 
È޽Ġ04-19  13:25~13:40 Break  () 
±³À°½Ã°£ 04-19 205È£ 13:40~14:00 In Memory of Hi Myung Park  Shung Chull Chae(Kyungpook National Univ. Korea) 
±³À°½Ã°£ 04-19 205È£ 14:00~14:20 Revascularization in Heart Failure: What We Now Know and Need to Still Learn  Eric Velaquez(Yale Univ. USA) 
È޽Ġ04-19  14:20~14:30 Break  () 
±³À°½Ã°£ 04-19 106È£ 14:30~14:45 Fibrinolytic Therapy Versus Primary PCI in STEMI  ½ÉµÎ¼±(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 04-19 106È£ 14:45~15:00 Can Beta-Blockers Be Terminated Post-MI? - Who Really Needs Them and How Long?  À±Ã¢È¯(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-19 106È£ 15:00~15:15 PCI Strategy in Multi Vessel Disease: How and When?  ¾È¼º±Õ(¿øÁÖÀÇ´ë) 
±³À°½Ã°£ 04-19 106È£ 15:15~15:30 Challenges in AMI: Personalized Cardiology in the Very Elderly Population  ÀÌ»ó¿±(ÃæºÏÀÇ´ë) 
Åä·Ð 04-19 106È£ 15:30~16:00 Discussion  () 
È޽Ġ04-19  16:00~16:10 Break  () 
±³À°½Ã°£ 04-19 205È£ 16:10~16:30 ÀÇ·áºÐÀïÀÇ ÇöȲ°ú ¿øÀΠ À̵¿ÇÐ(Çѱ¹ÀÇ·áºÐÀïÁ¶Á¤ÁßÀç¿ø) 
±³À°½Ã°£ 04-19 205È£ 16:30~16:50 ÀÇ·áºÐÀï(»ç°í)ÀÇ ¿Ã¹Ù¸¥ ÀÌÇØ¿Í ¿¹¹æ  À±ÅÂÁß(¹ý¹«¹ýÀΠŽÅ) 
±³À°½Ã°£ 04-19 205È£ 16:50~17:10 ÀÇ·áÇöÀå¿¡¼­ÀÇ ÀÇ·áÀο¡ ´ëÇÑ Æø¾ð°ú ÆøÇà: ÀÇ·áÀ±¸®Àû ´ëÃ¥  ±¸¿µ¸ð(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 04-19 205È£ 17:10~17:30 ÀÓ»óÀ±¸®ÀÇ ÀÌÇØ  ±Çº¹±Ô(ÀÌÈ­¿©´ë) 
Åä·Ð 04-19 205È£ 17:30~17:40 Discussion  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽÉÀåÇÐȸ 2019 Ãá°è½ÉÇ÷°üÅëÇÕÇмú´ëȸ : 2019-04-19""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÅëÁõÇÐȸ ÃæûÁöȸ Áý´ãȸ : 2019-04-19
´ÙÀ½±Û ¿¬¼¼¾Ïº´¿ø ´ëÇÑÁ¾¾ç³»°úÇÐȸ 4/18 ºÐ±âÁý´ãȸ : 2019-04-18
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 6 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 8 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 113 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 21 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 79 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 13 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 10 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 8 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 28 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 5 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 10 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 2 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 11 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 9 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 12 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷